Patent · US Active

Glucose responsive insulin delivery compositions and methods

US11896673B2 · kind B2 · utility

0Cited by
1References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMar 1, 2021
Grant dateFeb 13, 2024
Priority date—
Expiry dateJan 1, 2042

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07H13/08
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Disclosed herein is a glucose-responsive insulin delivery system based on the interaction between the glucose-modified insulin and glucose transporters (GLUTs) on erythrocytes (or red blood cells, RBCs). After being conjugated with glucose, insulin can efficiently bind to RBC membranes. The binding is reversible in the setting of hyperglycemia, resulting in fast release of insulin and subsequent drop of blood glucose (BG) level in vivo. In some embodiments, the delivery vehicle can include: 1) intravenously injectable polymeric nanoparticles (˜100 nm in diameter) coated with RBC membrane and loaded with glucose-modified insulin and/or 2) painless microneedle (MN) patches loaded with the complex of GLUT and glucose-modified insulin.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.